About Haemonetics (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100
Debt
Debt-to-Equity Ratio0.14%
Current Ratio1.82%
Quick Ratio1.33%
Price-To-Earnings
Trailing P/E Ratio41.80
Forward P/E Ratio40.99
P/E Growth3.32
Sales & Book Value
Annual Sales$886.12 million
Price / Sales4.60
Cash Flow$3.2567 per share
Price / Cash23.41
Book Value$14.22 per share
Price / Book5.36
Profitability
EPS (Most Recent Fiscal Year)$1.53
Net Income$-26,260,000.00
Net Margins-1.94%
Return on Equity12.39%
Return on Assets7.66%
Miscellaneous
Employees3,107
Outstanding Shares53,450,000
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics announced that its board has approved a stock repurchase program on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics (NYSE:HAE) announced its earnings results on Tuesday, February, 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.18. The medical instruments supplier had revenue of $234.04 million for the quarter, compared to the consensus estimate of $227.79 million. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. Haemonetics's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.43 earnings per share. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $1.80-1.90 for the period, compared to the Thomson Reuters consensus estimate of $1.70.
What price target have analysts set for HAE?
6 brokers have issued 1 year price targets for Haemonetics' stock. Their forecasts range from $50.00 to $80.00. On average, they anticipate Haemonetics' stock price to reach $70.00 in the next year. View Analyst Ratings for Haemonetics.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR) and Mazor Robotics (MZOR).
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, Chief Exec. Officer, Pres and Director (Age 54)
- Mr. William P. Burke, Chief Financial Officer and Exec. VP
- Mr. Neil Ryding, Exec. VP of Global Operations (Age 57)
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
- Mr. Gerard J. Gould, VP of Investor Relations (Age 64)
Has Haemonetics been receiving favorable news coverage?
Headlines about HAE stock have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics earned a news impact score of 0.24 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $76.24.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $4.07 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or $1.53 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Haemonetics (NYSE:HAE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Haemonetics in the last 12 months. Their average twelve-month price target is $70.00, suggesting that the stock has a possible downside of 8.18%. The high price target for HAE is $80.00 and the low price target for HAE is $50.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.50 |
Ratings Breakdown: | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $70.00 | $70.00 | $56.60 | $44.60 |
Price Target Upside: | 8.18% downside | 2.13% upside | 9.73% downside | 3.84% downside |
Haemonetics (NYSE:HAE) Consensus Price Target History

Haemonetics (NYSE:HAE) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Haemonetics (NYSE:HAE) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
Haemonetics (NYSE HAE) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/6/2018 | Dan Goldstein | VP | Sell | 518 | $54.65 | $28,308.70 | 4,002 | |
3/6/2018 | Jacqueline Scanlan | SVP | Sell | 114 | $72.23 | $8,234.22 | | |
3/6/2018 | Michelle L. Basil | EVP | Sell | 389 | $72.23 | $28,097.47 | | |
1/2/2018 | Mark W Kroll | Director | Sell | 7,118 | $63.00 | $448,434.00 | 33,881 | |
12/1/2017 | Pedro P Granadillo | Director | Sell | 7,118 | $57.06 | $406,153.08 | 31,663 | |
11/16/2017 | Ronald G Gelbman | Director | Sell | 5,440 | $56.69 | $308,393.60 | | |
11/14/2017 | Willaim P Burke | CFO | Sell | 13,193 | $54.04 | $712,949.72 | 27,227 | |
11/13/2017 | Dan Goldstein | CAO | Sell | 4,691 | $54.93 | $257,676.63 | 3,747 | |
11/10/2017 | Susan Bartlett Foote | Director | Sell | 16,926 | $54.19 | $917,219.94 | 27,313 | |
5/22/2017 | Ronald Merriman | Director | Sell | 17,471 | $40.33 | $704,605.43 | 24,925 | |
12/12/2016 | Ronald G Gelbman | Director | Sell | 5,683 | $40.30 | $229,024.90 | 49,688 | |
8/17/2016 | Ronald Merriman | Director | Sell | 4,337 | $35.14 | $152,402.18 | 22,088 | |
8/4/2016 | Christopher Simon | CEO | Buy | 60,000 | $35.00 | $2,100,000.00 | | |
10/26/2015 | Byron Selman | Insider | Sell | 344 | $32.13 | $11,052.72 | 12,010 | |
10/26/2015 | Christopher J Lindop | CFO | Sell | 436 | $32.13 | $14,008.68 | 45,350 | |
10/26/2015 | Sandra Jesse | EVP | Sell | 778 | $32.13 | $24,997.14 | 20,096 | |
10/26/2015 | Susan M Hanlon | VP | Sell | 497 | $32.13 | $15,968.61 | 20,464 | |
9/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $35.15 | $230,900.35 | 147,040 | |
9/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $35.63 | $169,776.95 | 147,040 | |
8/20/2015 | Christopher J. Lindop | CFO | Sell | 4,902 | $38.49 | $188,677.98 | 38,188 | |
8/17/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.28 | $258,030.32 | | |
7/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $39.09 | $191,619.18 | | |
7/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.59 | $260,066.71 | | |
7/6/2015 | Peter M Allen | Insider | Sell | 30,494 | $40.19 | $1,225,553.86 | | |
7/2/2015 | Jonathan White | Insider | Sell | 2,385 | $41.14 | $98,118.90 | | |
6/22/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $42.51 | $208,384.02 | | |
6/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $42.51 | $279,248.19 | | |
6/10/2015 | Susan M Hanlon | VP | Sell | 6,000 | $43.00 | $258,000.00 | | |
6/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $41.39 | $197,223.35 | | |
5/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.65 | $204,168.30 | | |
5/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $40.74 | $194,126.10 | | |
4/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.55 | $203,678.10 | | |
4/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.51 | $212,090.15 | | |
3/27/2015 | Susan M Hanlon | VP | Sell | 7,000 | $43.46 | $304,220.00 | | |
3/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $44.26 | $216,962.52 | | |
3/10/2015 | Susan Bartlett Foote | Director | Sell | 11,328 | $43.84 | $496,619.52 | | |
3/5/2015 | Ronald G Gelbman | Director | Sell | 7,707 | $44.76 | $344,965.32 | | |
3/4/2015 | Ronald Merriman | Director | Sell | 14,258 | $43.80 | $624,500.40 | | |
3/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.41 | $211,613.65 | | |
2/18/2015 | Pedro P Granadillo | Director | Sell | 11,328 | $43.45 | $492,201.60 | | |
2/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $39.15 | $186,549.75 | | |
1/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $37.20 | $177,258.00 | | |
12/1/2014 | Brian Concannon | CEO | Sell | 4,765 | $36.72 | $174,970.80 | | |
11/3/2014 | Brian Concannon | CEO | Sell | 4,765 | $35.86 | $170,872.90 | | |
10/13/2014 | Peter M Allen | Insider | Sell | 36,426 | $35.22 | $1,282,923.72 | | |
8/12/2014 | Ronald Merriman | Director | Sell | 13,602 | $35.76 | $486,407.52 | | |
8/1/2014 | Brian Concannon | CEO | Sell | 4,380 | $35.27 | $154,482.60 | | |
7/7/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $35.97 | $209,956.89 | | |
6/12/2014 | Ronald G Gelbman | Director | Sell | 9,184 | $34.00 | $312,256.00 | | |
6/6/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $34.69 | $202,485.53 | | |
5/12/2014 | Susan Bartlett Foote | Director | Sell | 9,184 | $33.16 | $304,541.44 | 9,939 | |
5/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.14 | $181,764.18 | 14,901 | |
5/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $30.01 | $138,046.00 | 130,307 | |
4/28/2014 | Peter Allen | Insider | Sell | 30,000 | $30.70 | $921,000.00 | 28,950 | |
4/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.98 | $186,667.26 | 14,901 | |
4/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $32.71 | $150,466.00 | 130,307 | |
3/6/2014 | Ronald Gelbman | Director | Sell | 12,000 | $36.17 | $434,040.00 | 39,173 | |
3/3/2014 | Brian Concannon | CEO | Sell | 4,600 | $36.36 | $167,256.00 | 130,307 | |
2/18/2014 | Susan Hanlon | VP | Sell | 3,690 | $39.00 | $143,910.00 | 16,905 | |
2/7/2014 | Jonathan White | Insider | Sell | 1,880 | $38.66 | $72,680.80 | 25,166 | |
2/3/2014 | Brian Concannon | CEO | Sell | 7,600 | $37.63 | $285,988.00 | 130,307 | |
1/27/2014 | Susan Hanlon | VP | Sell | 3,206 | $38.37 | $123,014.22 | 16,905 | |
1/10/2014 | Susan Hanlon | VP | Sell | 4,000 | $41.80 | $167,200.00 | 16,905 | |
1/2/2014 | Brian Concannon | CEO | Sell | 7,600 | $41.58 | $316,008.00 | 130,307 | |
12/16/2013 | Susan Hanlon | VP | Sell | 4,000 | $43.50 | $174,000.00 | 16,905 | |
12/9/2013 | Susan Hanlon | VP | Sell | 3,138 | $43.07 | $135,153.66 | 16,905 | |
12/2/2013 | Brian Concannon | CEO | Sell | 7,600 | $42.31 | $321,556.00 | 130,307 | |
11/12/2013 | Michael Kelly | Insider | Sell | 61,400 | $39.70 | $2,437,580.00 | 10,987 | |
11/1/2013 | Brian Concannon | CEO | Sell | 7,600 | $39.96 | $303,696.00 | | |
10/14/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.41 | $56,574.00 | 11,337 | |
9/13/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.36 | $56,504.00 | 11,337 | |
9/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $39.87 | $518,310.00 | 115,798 | |
8/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $42.24 | $549,120.00 | | |
7/12/2013 | Michael P Kelly | Insider | Sell | 1,400 | $44.10 | $61,740.00 | | |
7/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.87 | $544,310.00 | | |
6/18/2013 | Christopher J Lindop | CFO | Sell | 68,628 | $42.50 | $2,916,690.00 | | |
6/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $42.17 | $59,038.00 | | |
6/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.15 | $534,950.00 | | |
5/21/2013 | Christopher J Lindop | CFO | Sell | 42,882 | $42.00 | $1,801,044.00 | | |
5/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $39.66 | $55,524.00 | | |
5/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $38.66 | $502,580.00 | | |
12/3/2012 | Brian Concannon | CEO | Sell | 13,000 | $40.75 | $529,750.00 | | |
11/12/2012 | Pedro P Granadillo | Director | Sell | 16,000 | $80.40 | $1,286,400.00 | | |
9/4/2012 | Brian Concannon | CEO | Sell | 6,500 | $73.68 | $478,920.00 | | |
9/4/2012 | Christopher J Lindop | CFO | Sell | 61,783 | $74.34 | $4,592,948.22 | | |
(Data available from 1/1/2013 forward)
Haemonetics (NYSE HAE) News Headlines
Source: |
|
Haemonetics (NYSE:HAE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement
Haemonetics (NYSE HAE) Stock Chart for Tuesday, April, 24, 2018
Loading chart…